Latest Results from an Ongoing First-in-Human Phase 1a/b Study of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory CLL and Other B-cell Malignancies
Sunday, June 16, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Nurix is conducting a Phase 1a/b study of NX-5948, a selective BTK degrader, targeting patients with relapsed/refractory CLL and other B-cell malignancies. The study aims to explore the drug's efficacy and safety profile. This research reflects Nurix's commitment to developing novel therapies for challenging diseases.
Price reaction · baseline $15.18 (2024-06-14 close) · clean, no other NRIX news in the window
day 0 close
+0.7%
day 1
+21.5%
day 3 · peak
+40.3%
Market Sentiment Analysis
POSITIVE FACTORS
Ongoing Phase 1a/b study indicates progress in drug development.
Focus on innovative therapies for cancer and autoimmune diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-5948?
NX-5948 is a selective Bruton’s Tyrosine Kinase (BTK) degrader.
What type of study is being conducted?
A Phase 1a/b study is currently ongoing for NX-5948.
What conditions are targeted in the study?
The study targets patients with relapsed/refractory CLL and other B-cell malignancies.